Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 35% ± 16% | |
intestine | 11 studies | 37% ± 19% | |
kidney | 8 studies | 44% ± 16% | |
uterus | 6 studies | 39% ± 13% | |
liver | 6 studies | 35% ± 11% | |
eye | 5 studies | 36% ± 18% | |
brain | 5 studies | 28% ± 11% | |
lymph node | 5 studies | 32% ± 15% | |
skin | 4 studies | 40% ± 16% | |
breast | 4 studies | 38% ± 17% | |
ovary | 3 studies | 28% ± 8% | |
adrenal gland | 3 studies | 40% ± 8% | |
esophagus | 3 studies | 33% ± 8% | |
pancreas | 3 studies | 27% ± 8% | |
stomach | 3 studies | 25% ± 4% | |
prostate | 3 studies | 55% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 89% | 7918.39 | 1285 / 1445 | 98% | 131.40 | 179 / 183 |
uterus | 84% | 11433.17 | 142 / 170 | 100% | 201.76 | 457 / 459 |
prostate | 82% | 9506.17 | 200 / 245 | 100% | 194.36 | 502 / 502 |
ovary | 80% | 17205.71 | 144 / 180 | 100% | 111.40 | 429 / 430 |
bladder | 81% | 14063.14 | 17 / 21 | 99% | 188.01 | 498 / 504 |
kidney | 89% | 14986.02 | 79 / 89 | 87% | 69.26 | 787 / 901 |
intestine | 80% | 8681.30 | 775 / 966 | 96% | 141.41 | 505 / 527 |
adrenal gland | 81% | 9223.08 | 209 / 258 | 93% | 121.04 | 214 / 230 |
lung | 74% | 24601.93 | 425 / 578 | 97% | 131.57 | 1124 / 1155 |
thymus | 70% | 9492.80 | 460 / 653 | 98% | 106.30 | 594 / 605 |
brain | 82% | 11807.00 | 2161 / 2642 | 78% | 79.53 | 553 / 705 |
stomach | 64% | 7849.82 | 231 / 359 | 92% | 101.80 | 264 / 286 |
skin | 63% | 4306.63 | 1135 / 1809 | 94% | 89.04 | 443 / 472 |
breast | 46% | 3110.79 | 212 / 459 | 99% | 149.30 | 1110 / 1118 |
liver | 73% | 10449.62 | 165 / 226 | 72% | 70.77 | 292 / 406 |
pancreas | 35% | 4368.88 | 115 / 328 | 96% | 146.83 | 170 / 178 |
tonsil | 0% | 0 | 0 / 0 | 100% | 161.20 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 90.22 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 85% | 44.74 | 68 / 80 |
heart | 78% | 11326.99 | 668 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 64% | 7883.60 | 849 / 1335 | 0% | 0 | 0 / 0 |
adipose | 60% | 7925.38 | 721 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 48% | 13104.57 | 447 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 41% | 22.00 | 12 / 29 |
spleen | 31% | 8327.34 | 75 / 241 | 0% | 0 | 0 / 0 |
muscle | 30% | 1952.50 | 241 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0090084 | Biological process | negative regulation of inclusion body assembly |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_1903265 | Biological process | positive regulation of tumor necrosis factor-mediated signaling pathway |
GO_0006402 | Biological process | mRNA catabolic process |
GO_0034605 | Biological process | cellular response to heat |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0071383 | Biological process | cellular response to steroid hormone stimulus |
GO_1901673 | Biological process | regulation of mitotic spindle assembly |
GO_0046034 | Biological process | ATP metabolic process |
GO_0070370 | Biological process | cellular heat acclimation |
GO_0031396 | Biological process | regulation of protein ubiquitination |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0034599 | Biological process | cellular response to oxidative stress |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0050821 | Biological process | protein stabilization |
GO_0070434 | Biological process | positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway |
GO_0090063 | Biological process | positive regulation of microtubule nucleation |
GO_0032757 | Biological process | positive regulation of interleukin-8 production |
GO_0042026 | Biological process | protein refolding |
GO_0045648 | Biological process | positive regulation of erythrocyte differentiation |
GO_2001240 | Biological process | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand |
GO_0051085 | Biological process | chaperone cofactor-dependent protein refolding |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0005576 | Cellular component | extracellular region |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0016607 | Cellular component | nuclear speck |
GO_0005813 | Cellular component | centrosome |
GO_0016235 | Cellular component | aggresome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005925 | Cellular component | focal adhesion |
GO_0005814 | Cellular component | centriole |
GO_0016234 | Cellular component | inclusion body |
GO_0072562 | Cellular component | blood microparticle |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0031982 | Cellular component | vesicle |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0140545 | Molecular function | ATP-dependent protein disaggregase activity |
GO_0055131 | Molecular function | C3HC4-type RING finger domain binding |
GO_0044183 | Molecular function | protein folding chaperone |
GO_0031072 | Molecular function | heat shock protein binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0001618 | Molecular function | virus receptor activity |
GO_0051082 | Molecular function | unfolded protein binding |
GO_0001664 | Molecular function | G protein-coupled receptor binding |
GO_0042826 | Molecular function | histone deacetylase binding |
GO_0140662 | Molecular function | ATP-dependent protein folding chaperone |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | HSPA1B |
Protein name | Heat shock 70 kDa protein 1B (Heat shock 70 kDa protein 2) (HSP70-2) (HSP70.2) Heat shock 70 kDa protein 1B |
Synonyms | HSP72 |
Description | FUNCTION: Molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. Plays a pivotal role in the protein quality control system, ensuring the correct folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins for subsequent degradation. This is achieved through cycles of ATP binding, ATP hydrolysis and ADP release, mediated by co-chaperones. The co-chaperones have been shown to not only regulate different steps of the ATPase cycle, but they also have an individual specificity such that one co-chaperone may promote folding of a substrate while another may promote degradation. The affinity for polypeptides is regulated by its nucleotide bound state. In the ATP-bound form, it has a low affinity for substrate proteins. However, upon hydrolysis of the ATP to ADP, it undergoes a conformational change that increases its affinity for substrate proteins. It goes through repeated cycles of ATP hydrolysis and nucleotide exchange, which permits cycles of substrate binding and release. The co-chaperones are of three types: J-domain co-chaperones such as HSP40s (stimulate ATPase hydrolysis by HSP70), the nucleotide exchange factors (NEF) such as BAG1/2/3 (facilitate conversion of HSP70 from the ADP-bound to the ATP-bound state thereby promoting substrate release), and the TPR domain chaperones such as HOPX and STUB1 . Maintains protein homeostasis during cellular stress through two opposing mechanisms: protein refolding and degradation. Its acetylation/deacetylation state determines whether it functions in protein refolding or protein degradation by controlling the competitive binding of co-chaperones HOPX and STUB1. During the early stress response, the acetylated form binds to HOPX which assists in chaperone-mediated protein refolding, thereafter, it is deacetylated and binds to ubiquitin ligase STUB1 that promotes ubiquitin-mediated protein degradation . Regulates centrosome integrity during mitosis, and is required for the maintenance of a functional mitotic centrosome that supports the assembly of a bipolar mitotic spindle . Enhances STUB1-mediated SMAD3 ubiquitination and degradation and facilitates STUB1-mediated inhibition of TGF-beta signaling . Essential for STUB1-mediated ubiquitination and degradation of FOXP3 in regulatory T-cells (Treg) during inflammation . .; FUNCTION: (Microbial infection) In case of rotavirus A infection, serves as a post-attachment receptor for the virus to facilitate entry into the cell. . |
Accessions | ENST00000417199.4 A0A0G2JIW1 ENST00000450744.1 ENST00000445736.1 ENST00000375650.5 ENST00000391555.1 ENST00000391548.1 ENST00000545241.2 P0DMV9 ENST00000458062.3 |